论文部分内容阅读
目的:探讨吡格列酮对肥胖型2型糖尿病患者血清抵抗素的影响。方法:将50例初诊肥胖2型糖尿病患者随机分两组,分别给予二甲双胍(M组)和二甲双胍联合吡格列酮(MP组)治疗12周,于治疗前后测定受试者空腹血清抵抗素、血糖(FBS)、血脂、胰岛素(FINS),测量身高、体重,计算体重指数(BMI)、胰岛素抵抗指数(HOMA-IR)。结果:与治疗前相比,MP组FBS、FINS、HOMA-IR、抵抗素水平明显降低(P<0.01);M组抵抗素水平没有明显改变(P>0.05),BMI、FINS、HOMA-IR水平明显降低(P<0.01)。结论:吡格列酮治疗能有效降低肥胖型2型糖尿病患者血清抵抗素水平。
Objective: To investigate the effect of pioglitazone on serum resistin in obese type 2 diabetic patients. Methods: Fifty newly diagnosed obese type 2 diabetic patients were randomly divided into two groups: metformin (M group) and metformin combined with pioglitazone (MP group) for 12 weeks. The levels of fasting serum resistin, blood glucose ), Lipids, insulin (FINS), height, weight, body mass index (BMI) and insulin resistance index (HOMA-IR). Results: The levels of FBS, FINS, HOMA-IR and resistin in MP group were significantly lower than those in the control group (P <0.01). The levels of resistin in M group were not significantly changed (P> 0.05) The level was significantly lower (P <0.01). Conclusion: Pioglitazone can effectively reduce the level of serum resistin in obese type 2 diabetic patients.